OP
CRNX icon

ORG Partners’s Crinetics Pharmaceuticals CRNX Stock Holding History

ORG Partners’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$6.79K Buy
146
+119
+441% +$5.3K ﹤0.01% 1132
2025
Q3 		$1.12K Buy
+27
New +$863 ﹤0.01% 1385

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

ORG Partners's CRNX Position: Q4 2025 in Review

ORG Partners increased its Crinetics Pharmaceuticals (CRNX) stake by 441% in Q4 2025, buying an estimated $5.3K and bringing the position to 146 shares worth $6.79K. The position accounts for ﹤0.01% of the portfolio, ranked #1132.

ORG Partners first reported a position in CRNX in Q3 2025 and has held it in 2 quarters since. 240 funds tracked by Wall St. Rank hold CRNX as of Q4 2025.

  • ORG Partners held 146 shares of Crinetics Pharmaceuticals worth $6.79K as of Q4 2025.
  • ORG Partners bought 119 Crinetics Pharmaceuticals shares in Q4 2025, an estimated $5.3K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of ORG Partners's portfolio in Q4 2025, its #1132 holding.
  • ORG Partners first reported a position in Crinetics Pharmaceuticals in Q3 2025 and has held it in 2 quarters since.
  • 240 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2025.

Based on ORG Partners's 13F filing for Q4 2025, filed 14 Jan 2026.